Drugs / Limaprost
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02125981 | Sep 2014 → Oct 2022 | spinal cord disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01888536 | Feb → Oct 2013 | spinal stenosis | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Limaprost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01888536 ↗ |
| Known as | limaprost alfadex | “The limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.” NCT02125981 ↗ |
| Modality | Small molecule | — CHEMBL2107456 ↗ |
| Route | Oral | “Oral Limaprost Administration” NCT02125981 ↗ |